[Outcome of Eight-Year-Experiences of BCG Intravesical Instillation Therapy in Patients with Non-Muscle Invasive Bladder Cancer in Asahikawa Medical University Hospital].

We retrospectively investigated the outcome of BCG intravesical instillation therapy for patients with non-muscle invasive bladder cancer. From 2011 to 2019, a total of 79 patients had received BCG intravesical instillation therapy for non-muscle invasive bladder cancer. Of these 79 patients, 62 were included in this study. The protocol of BCG intravesical instillation therapy was as follows: instillation once per week for 6 consecutive weeks as induction, followed by instillation twice (once per week for 2 consecutive weeks) at each of 4, 6 and 12 months after TUR-BT as maintenance. BCG completion rate was 42%. The most frequent reasons for BCG discontinuation were adverse events of BCG treatment (70%). Two-year bladder non-recurrence survival was 72%. BCG completion group showed a statistically significant better bladder non-recurrence survival compared to BCG non-completion group. However, when we focused on the patients who discontinued BCG treatment only due to adverse events, bladder non-recurrence survival in this patient group was not different from BCG completion group. In conclusion, adverse events resulting in discontinuation of BCG treatment seem to be a prognostic factor for the efficacy of BCG treatment. But from the perspective of patient's quality of life, a better management is required to prevent adverse events of BCG treatment and to promote the BCG completion rate.